<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations/><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9"><gtr:id>3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9</gtr:id><gtr:name>University of Oxford</gtr:name><gtr:department>Psychiatry</gtr:department><gtr:address><gtr:line1>University Chest</gtr:line1><gtr:line2>Wellington Square</gtr:line2><gtr:line4>Oxford</gtr:line4><gtr:postCode>OX1 2JD</gtr:postCode><gtr:region>South East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9"><gtr:id>3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9</gtr:id><gtr:name>University of Oxford</gtr:name><gtr:address><gtr:line1>University Chest</gtr:line1><gtr:line2>Wellington Square</gtr:line2><gtr:line4>Oxford</gtr:line4><gtr:postCode>OX1 2JD</gtr:postCode><gtr:region>South East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/8CB2FBAC-797E-4A4C-9B42-3B343A0266D6"><gtr:id>8CB2FBAC-797E-4A4C-9B42-3B343A0266D6</gtr:id><gtr:firstName>Guy</gtr:firstName><gtr:surname>Goodwin</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/382F3EEB-8130-4EB4-9046-EC4190AD6E07"><gtr:id>382F3EEB-8130-4EB4-9046-EC4190AD6E07</gtr:id><gtr:firstName>Philip</gtr:firstName><gtr:otherNames>John</gtr:otherNames><gtr:surname>Cowen</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/C50EE9C0-A0E3-4EB0-9EFD-C424F4204D12"><gtr:id>C50EE9C0-A0E3-4EB0-9EFD-C424F4204D12</gtr:id><gtr:firstName>Catherine</gtr:firstName><gtr:surname>Harmer</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=G0801432"><gtr:id>A6DB6EB8-7E93-4658-BD7C-92D2812C4F92</gtr:id><gtr:title>Cognitive biomarkers of antidepressant drug efficacy</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Research Grant</gtr:grantCategory><gtr:grantReference>G0801432</gtr:grantReference><gtr:abstractText>Clinical depression is a common and extremely disabling condition. Although drug treatments for depression exist, these do not work for a substantial proportion of patients and for some they may only reduce the symptoms rather than allowing a full recovery. One of the problems with developing new more effective treatments is that the drugs need to be tested in clinical trials with depressed patients, which takes a lot of time and is very costly. In addition, a significant number of drugs may tested in this way are found, in fact, to be ineffective. One way of improving the development of new drugs is to have models which are able to predict the likely success of new treatments. At the moment this is carried out with animal models, but these often fail to capture human aspects of depression which involves negative thoughts and beliefs. We have developed some models for use with healthy volunteers which are sensitive to antidepressant drug action and which examine how people deal with emotional information. This work suggests that antidepressants increase how we attend to, recognise and remember positive emotional information such as happy facial expressions of emotion. The current application aims to explore this in more detail and confirm whether these effects are seen with different kinds of antidepressant drug treatments. This will help us understand whether these emotional changes occur irrespective of the precise way in which the drug affects the chemicals in the brain and also to what extent these models can predict whether a drug will be good for depression or for anxiety symptoms. We will also test whether these models could have predicted drug treatments which have failed to work in depression (though did work in the animal models) and finally whether these models can help identify drugs which may increase the likelihood of depression and which may therefore need to be used with caution in people at high risk of developing depression. These studies will help us understand what makes a good treatment for depression. Also this will develop the use of these models for the screening and detection of novel treatments which have particular promise for depression, therefore reducing the low hit rate of successful treatments in the clinic and speeding up the drug discovery process.</gtr:abstractText><gtr:technicalSummary>Depression is a common condition associated with very substantial health disabilities and limited treatment options. The major bottleneck in improving drug treatment is the lack of valid animal models; this hinders translation of new therapies from the bench into the clinic. Human cognitive biomarker models may be better placed to detect and understand neuropsychological processes in this uniquely human disorder. Such models could be invaluable in enabling better selection of novel antidepressant compounds for subsequent randomised clinical trials and in providing a likely indication of their overall therapeutic profile. Equally, valid human biomarkers might be helpful in identifying drugs with a significant risk of provoking depression during clinical use. There is now substantial evidence that negative biases in the processing of emotional information play a key role in the onset and maintenance of clinical mood disorders. We have shown that antidepressant treatment in healthy subjects produces biases in tasks of emotional processing that essentially are the opposite of those seen in depression. The aim of the present application is to validate these tasks as effective cognitive biomarkers of antidepressant action applicable to the assessment of the novel candidate compounds by assessing the following hypotheses 1) that early effects on emotional processing also occur with antidepressants acting via different mechanisms 2) that these cognitive biomarkers can distinguish agents which have antidepressant activity from those whose therapeutic effects are confined to anxiety disorders; 3) that our cognitive biomarkers are able to screen out ?false positives? by exploring the failed Nk1 antagonist aprepitant 4) that these biomarkers will be able to detect agents likely to cause depression as an adverse effect. These studies should provide validation of a cognitive biomarker approach for screening and understanding novel candidate agents in an area of high unmet need.</gtr:technicalSummary><gtr:fund><gtr:end>2013-07-31</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2009-02-01</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>363831</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs/><gtr:disseminationOutputs><gtr:disseminationOutput><gtr:description>Cheltenham Science Festival</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>6A1DA06E-53A0-430E-A63A-AB1FC336E176</gtr:id><gtr:impact>200 people attended the presentations (Harmer, pariante and Ruby Wax) and we continued the discussion in a talking point afterwards. This provided a broad perspective on people interested in (and often treated for) depression and we were able to share our findings and learn from the response of the group.

Positive feedback was received from those attending.</gtr:impact><gtr:outcomeId>GduXcMHQ2hd</gtr:outcomeId><gtr:partOfOfficialScheme>true</gtr:partOfOfficialScheme><gtr:presentationType>Keynote/Invited Speaker</gtr:presentationType><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2012</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Scientific Mind Article</gtr:description><gtr:form>A magazine, newsletter or online publication</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>3409719C-ED71-4E56-94F8-98677FD2F0F3</gtr:id><gtr:impact>This publication will appear in December 2013.</gtr:impact><gtr:outcomeId>Qsh7NLuQBL6</gtr:outcomeId><gtr:partOfOfficialScheme>true</gtr:partOfOfficialScheme><gtr:presentationType>Paper Presentation</gtr:presentationType><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2013</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>BBC documentary</gtr:description><gtr:form>A press release, press conference or response to a media enquiry/interview</gtr:form><gtr:geographicReach>Regional</gtr:geographicReach><gtr:id>DDBBFF22-B3EB-4628-8B7F-5F085D1D3C8B</gtr:id><gtr:impact>This MRC work appeared in a BBC documentary 'the truth about depression', for Northen Ireland. This was aired in Febuary 2013. I received numerous contacts following this for more information from interested members of the public.

I received numerous contacts following this for more information from interested members of the public</gtr:impact><gtr:outcomeId>FRJfy2j3sbW</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:presentationType>Keynote/Invited Speaker</gtr:presentationType><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2012</gtr:year></gtr:disseminationOutput></gtr:disseminationOutputs><gtr:exploitationOutputs/><gtr:furtherFundingOutputs><gtr:furtherFundingOutput><gtr:amountPounds>1500000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Wellcome Trust Strategic Award</gtr:description><gtr:end>2016-06-02</gtr:end><gtr:fundingOrg>Wellcome Trust</gtr:fundingOrg><gtr:id>047421F4-82BB-45D3-83BA-C68757D9BACE</gtr:id><gtr:outcomeId>56d4299991ac18.95383752</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2014-10-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>300000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:department>UCB Celltech</gtr:department><gtr:description>UCB Alliance funding</gtr:description><gtr:end>2016-12-02</gtr:end><gtr:fundingOrg>UCB Pharma</gtr:fundingOrg><gtr:id>5EEB6199-4882-4919-A654-1FC538D6E4F8</gtr:id><gtr:outcomeId>56d429ee1297c4.97333090</gtr:outcomeId><gtr:sector>Private</gtr:sector><gtr:start>2013-10-01</gtr:start></gtr:furtherFundingOutput></gtr:furtherFundingOutputs><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs><gtr:productOutput><gtr:description>Our models of emotional processing are gaining increasing interest as biomarkers of effective antidepressant drug action. Collaborations with pharmaceutical industry have increased and we have used these models in phase 1 studies with novel compounds as proof of concept.</gtr:description><gtr:id>07412515-1088-4089-AD7E-7F96E135800F</gtr:id><gtr:impact>Increased funding from industry; useful information on dosing requirements for novel compounds.</gtr:impact><gtr:outcomeId>9FFCAF18696</gtr:outcomeId><gtr:stage>Early clinical assessment</gtr:stage><gtr:status>Actively seeking support</gtr:status><gtr:title>Biomarker : antidepressant drug action</gtr:title><gtr:type>Support Tool - For Medical Intervention</gtr:type><gtr:yearDevCompleted>2008</gtr:yearDevCompleted></gtr:productOutput></gtr:productOutputs><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs><gtr:researchMaterialOutput><gtr:description>This battery of emotional tasks was validated by the study conducted under this MRC award</gtr:description><gtr:id>D4F67022-EFE1-4D2C-BCDA-DEA8A52EAC70</gtr:id><gtr:impact>Interest and funding from the pharmaceutical industry</gtr:impact><gtr:outcomeId>F8541433241</gtr:outcomeId><gtr:providedToOthers>true</gtr:providedToOthers><gtr:title>Emotional Test Battery</gtr:title><gtr:type>Model of mechanisms or symptoms - human</gtr:type><gtr:yearFirstProvided>2009</gtr:yearFirstProvided></gtr:researchMaterialOutput></gtr:researchMaterialOutputs><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs><gtr:spinOutOutput><gtr:companyName>p1vital</gtr:companyName><gtr:description>www.p1vital.com</gtr:description><gtr:id>8B1096C4-B132-4F6F-A92F-E83E24C1BD67</gtr:id><gtr:impact>Steering experimental medicine models for CNS drug development</gtr:impact><gtr:outcomeId>gTbb4MyVp64</gtr:outcomeId><gtr:url>http://www.p1vital.com</gtr:url><gtr:yearCompanyFormed>2004</gtr:yearCompanyFormed></gtr:spinOutOutput></gtr:spinOutOutputs></gtr:output><gtr:publications><gtr:publication><gtr:id>E45D8371-C82B-4B30-9387-5FC45A79ECE3</gtr:id><gtr:title>Effects of 7 days of treatment with the cannabinoid type 1 receptor antagonist, rimonabant, on emotional processing.</gtr:title><gtr:parentPublicationTitle>Journal of psychopharmacology (Oxford, England)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/cc9a6a70cdcc515d2da40dad66f5d21a"><gtr:id>cc9a6a70cdcc515d2da40dad66f5d21a</gtr:id><gtr:otherNames>Horder J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0269-8811</gtr:issn><gtr:outcomeId>fp4aCWHaQqB</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>B4A37DD4-A6CF-4247-A774-203636C25905</gtr:id><gtr:title>Effects of short-term varenicline administration on emotional and cognitive processing in healthy, non-smoking adults: a randomized, double-blind, study.</gtr:title><gtr:parentPublicationTitle>Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/bd5fc490beb93ed4577e7c6082fe7d71"><gtr:id>bd5fc490beb93ed4577e7c6082fe7d71</gtr:id><gtr:otherNames>Mocking RJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0893-133X</gtr:issn><gtr:outcomeId>pm_13696_26_23072834</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>279AC739-9A6C-48F9-9FCD-8D0594CC326E</gtr:id><gtr:title>Acute fluoxetine modulates emotional processing in young adult volunteers.</gtr:title><gtr:parentPublicationTitle>Psychological medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/f2066727af80b3f62b763a681af70cd6"><gtr:id>f2066727af80b3f62b763a681af70cd6</gtr:id><gtr:otherNames>Capit?o LP</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0033-2917</gtr:issn><gtr:outcomeId>5675e23cc4506</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>B71B2114-88B1-4D53-9606-5D3948B18D40</gtr:id><gtr:title>Short-term NK1 receptor antagonism and emotional processing in healthy volunteers.</gtr:title><gtr:parentPublicationTitle>Psychopharmacology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/6aeda73005ba3b506f69f4a60f8cc0ca"><gtr:id>6aeda73005ba3b506f69f4a60f8cc0ca</gtr:id><gtr:otherNames>Pringle A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0033-3158</gtr:issn><gtr:outcomeId>d4XN121622u</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>E22BE7E0-5DFE-4EC8-B0B7-67E1A27A427C</gtr:id><gtr:title>Using an experimental medicine model to understand the antidepressant potential of the N-Methyl-D-aspartic acid (NMDA) receptor antagonist memantine.</gtr:title><gtr:parentPublicationTitle>Journal of psychopharmacology (Oxford, England)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/6aeda73005ba3b506f69f4a60f8cc0ca"><gtr:id>6aeda73005ba3b506f69f4a60f8cc0ca</gtr:id><gtr:otherNames>Pringle A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0269-8811</gtr:issn><gtr:outcomeId>pm_13696_26_22596208</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">G0801432</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>3C193D18-12BD-4B15-8347-037BA623E0FF</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>Mental Health</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>89AE580F-2437-4540-9640-37005C968E67</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>4.1  Discovery and preclinical testing of markers and technologies</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>